| gap-pubmed-20260410- | What molecular mechanisms mediate MSC-derived exosome neuroprotection in methamp | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does ADAM10 overexpression mechanistically improve learning, memory, and syn | open | 0.82 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What are the specific side effects and mechanisms of therapeutic ADAM10 enhancem | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do GR- and PR-DPRs mechanistically disrupt nuclear membrane integrity? | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines whether patients develop dying-back vs dying-forward pathology i | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do GP-DPRs activate MAPK signaling to disrupt axonal transport and synaptic | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the functional significance of VEGFA-polyphenol interactions at Glu64 an | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do tea polyphenols mechanistically interfere with calcium signaling and neur | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How can target specificity challenges for KEAP1-NRF2 modulators be overcome in n | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms underlie the dual role of NRF2 in neuroprotection versus cancer | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do HSV-gB-induced epigenetic changes translate to neuronal dysfunction and c | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms link HSV-gB to HDAC3/HDAC8 upregulation and chromatin | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do differentiation-based aging and amyloid models show opposite epigenetic s | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What upstream signaling pathways mediate Aβ-induced p39 S-nitrosylation? | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does Aβ-induced p39 S-nitrosylation lead to dendrite retraction and spine lo | open | 0.83 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What molecular mechanisms link S-nitrosylation of p39 at Cys265 to its degradati | open | 0.84 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Can randomized controlled trials confirm the neuroprotective effects observed in | open | 0.82 | 0.00 | 2026-04-10 | 0 | | clinical-neuroscience |
| gap-pubmed-20260410- | Why do GLP-1RAs reduce stroke risk but not intracerebral hemorrhage risk in diab | open | 0.80 | 0.00 | 2026-04-10 | 0 | | cerebrovascular |
| gap-pubmed-20260410- | What are the molecular mechanisms by which GLP-1RAs provide neuroprotective effe | partially_addressed | 0.89 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does the aged-like microglial signature mechanistically drive FTD-specific b | open | 0.72 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms link microglial TBK1 deficiency to T cell infiltration | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why does TBK1 deletion in motor neurons cause autophagy defects without transcri | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do organelle-specific selective autophagy pathways differentially contribute | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What specific mechanisms link selective autophagy dysfunction to neurodegenerati | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do antisense DMPK RNA foci accumulate to a lesser extent than sense foci dur | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms underlie congenital DM1 pathogenesis beyond RNA foci accumulatio | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do non-coding structural variants in DLG2 and NR3C2 promoters mechanisticall | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodevelopmental-disorders |
| gap-pubmed-20260410- | Why do inherited ASD variants enrich different biological pathways than de novo | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodevelopmental-disorders |
| gap-pubmed-20260410- | What are the direct molecular targets through which triptolide modulates Wnt/β-c | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does Wnt/β-catenin pathway inhibition provide neuroprotection when this path | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does anesthesia/surgery specifically impair the medial septum-hippocampal ch | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does CHRM1 activation mechanistically regulate BDNF/TrkB signaling in the hi | open | 0.84 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What are the specific circulating factors in exercise-conditioned plasma that me | partially_addressed | 0.89 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the extreme variability in age of onset and muscle distribution | open | 0.68 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do mutations in the same genes cause either dominant or recessive inheritanc | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms explain how SQSTM1 mutations cause distal myopathy onl | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How can MS4A inhibition be therapeutically targeted without disrupting beneficia | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the molecular mechanism by which MS4A4A and MS4A6A cooperatively restrai | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do seven different PFBC genes converge on the same calcium deposition phenot | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms drive selective calcium-hydroxyapatite deposition in b | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do neuroinflammation biomarkers mechanistically relate to neurodegeneration | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What factors determine the validity and clinical utility limitations of emerging | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why are neurons specifically susceptible to NLRP3-mediated pyroptosis compared t | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do post-translational modifications regulate NLRP3 inflammasome activation i | open | 0.81 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What specific mechanisms drive NLRP3 inflammasome activation in different neurod | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What mechanisms underlie the aggregate vascular risk effect when individual fact | open | 0.75 | 0.00 | 2026-04-10 | 0 | | cerebrovascular |
| gap-pubmed-20260410- | Why does cerebrovascular pathology associate with lower Braak staging in Alzheim | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do age at exposure, gender, and substance abuse modulate CTE development and | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms drive the characteristic perivascular clustering of tau patholog | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What genetic risk factors predispose individuals to developing CTE following rep | partially_addressed | 0.89 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |